Product
Balversa
1 clinical trial
9 indications
Indication
Bladder CancerIndication
Urothelial CarcinomaIndication
Bladder Urothelial CarcinomaIndication
FGFR MutationIndication
FGFR2 Gene MutationIndication
FGFR3 Gene MutationIndication
FGFR2 AmplificationIndication
Metastatic Urothelial CarcinomaIndication
Bladder CarcinomaClinical trial
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving ErdafitinibStatus: Terminated, Estimated PCD: 2022-12-20